Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONTACT<br />
Vincent Lefaiconnier<br />
Chief Commercial Officer<br />
ADDRESS<br />
Vexim<br />
75 rue Saint Jean<br />
31130 Balma<br />
France<br />
TELEPHONE<br />
+33 4 61 48 48 38<br />
FAX<br />
+33 5 61 48 95 19<br />
EMAIL<br />
v.lefauconnier@vexim.fr<br />
YEAR FOUNDED<br />
2006<br />
Vexim<br />
www.vexim.fr<br />
FINANCIAL SUMMARY<br />
Half-year 2012 sales: €1.1m (+93% over 12 months)<br />
Full-year 2011 sales: €1.2m<br />
2011 net income: -€5.1m<br />
COMPANY PROFILE<br />
Based in Balma, near Toulouse (France), Vexim is a medical device specialist created in February 2006. The<br />
company has specialised in the creation and marketing of mini-invasive solutions for treating spinal pathologies.<br />
Benefitting from the financial support of its longstanding shareholders, Truffle Capital and Banexi Venture, and<br />
from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable<br />
of repairing a deformed or fractured vertebra and correcting the anatomy of the spinal column. The Company<br />
currently has 35 staff. It has its own sales teams in France, Germany and Italy, as well as distributors in Spain,<br />
Portugal, Italy, Turkey, Argentina and South Africa. The company’s 2011 sales amounted to €1.2m and its 2011<br />
gross margin was 58.3%. Vexim was successfully listed on NYSE Alternext in May 2012, raising €11m. The<br />
company’s 1st half 2012 sales achieved €1.1m, almost equaling the whole 2011 financial year performance.<br />
MANAGEMENT<br />
Vincent Gardès, Chief Executive Officer<br />
Vincent Lefauconnier, Chief Commercial Officer<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language